Lv2
140 积分 2023-04-19 加入
An Antibody–Oligonucleotide Conjugate for Myotonic Dystrophy Type 1
19天前
已完结
The next generation of antibody–drug conjugates
25天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation
1个月前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1个月前
已完结
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
1个月前
已完结
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases
2个月前
已完结
Amphiregulin and Fibrosis: Existing Evidence and Future Directions
2个月前
已关闭
RIPK2 inhibitors for disease therapy: Current status and perspectives
2个月前
已完结
皖公网安备34019202002308
